IL22 and atopic eczema: First, the efficacy of the anti-IL-22 antibody fezakinumab was demonstrated in a randomized controlled trial in atopic dermatitis, a disease which shares many pathophysiological features with asthma and especially neutrophilic asthma (tissue remodeling, neutrophilic inflammation) (222).